Q-omics provides the consensus-scored SLC35G6 profile across patient tissues and cancer cell-line models. SLC35G6 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, SLC35G6 is differentially expressed in 9, with the highest sampling consensus in UCEC. Additionally, SLC35G6 RNA expression shows 14,802 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUSC, UCEC, and TGCT as cancer lineages where SLC35G6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC35G6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC35G6 survival associations across molecular data types. SLC35G6 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC35G6 RNA expression–survival associations across cancer types. High SLC35G6 expression shows unfavorable associations in LUSC, THCA and SKCM, but favorable associations in HNSC, ACC and SCLC. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for SLC35G6 RNA expression.
This table summarizes SLC35G6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for SLC35G6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC35G6 shows lower tumor expression in THCA and higher tumor expression in UCEC, LIHC, CHOL, HNSC and STAD. The UCEC box plot shows higher SLC35G6 RNA expression in tumor versus normal tissue (log2 FC = +0.091, t-test p = .004).
This table shows molecular features associated with SLC35G6 in patient tissues and cancer cell lines. In patient samples, SLC35G6 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC35G6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SOFT_TISSUE.
